查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1982509

全球生長抑制素類似物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Somatostatin Analogs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計生長抑制素類似物市場將從 2025 年的 94.9 億美元成長到 2034 年的 174.9 億美元，2026 年至 2034 年的複合年成長率為 7.02%。

由於荷爾蒙相關疾病和某些類型腫瘤病例的增加，全球生長抑制素類似物市場正經歷穩定成長。生長抑制素類似物是用於調節荷爾蒙分泌的合成藥物，常用於治療肢端肥大症和神經內分泌腫瘤等疾病。人們對內分泌疾病的認知不斷提高，診斷技術的進步也促進了疾病的早期發現和治療。隨著醫療保健系統擴大專科治療的覆蓋範圍，生長抑制素類似物製劑在醫院和專科診所的使用量也不斷增加。

推動市場發展的因素有很多。荷爾蒙失調和神經內分泌腫瘤的日益普遍，使得對有效長期治療方法的需求不斷成長。藥廠正加大研發投入，以改善藥物配方並延長藥效持續時間。此外，發展中地區醫療基礎設施的改善和醫療支出的成長，也提高了病患的就醫機會。政府對罕見疾病治療計畫的支持，也對市場擴張起到了促進作用。

隨著醫學研究不斷探索新的治療應用，生長抑制素類似物市場前景光明。藥物遞送系統的進步，包括長效注射劑型，可望提高患者的用藥便利性和治療效果。生技公司和製藥公司之間合作的加強有望加速產品研發。隨著人們對內分泌疾病的認知不斷提高以及診斷能力的增強，未來幾年對有效荷爾蒙調節療法的需求預計將會成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球生長抑制素類似物市場：依類型分類

  • 市場分析、洞察與預測
  • Octreotide
  • Lanreotide
  • Pasireotide

第5章：全球生長抑制素類似物市場：依應用領域分類

  • 市場分析、洞察與預測
  • 肢端肥大症
  • 神經內分泌腫瘤（NETs）
  • 其他

第6章 全球生長抑制素類似物市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd
    • Midatech Pharma PLC
    • Ipsen Pharma
    • Chiasma Inc
    • Peptron Inc
    • Crinetics Pharmaceuticals
    • Dauntless Pharmaceuticals
    • Camurus AB
    • Teva Pharmaceuticals Inc
    • Pfizer Inc
簡介目錄
Product Code: VMR11212122

The Somatostatin Analogs Market size is expected to reach USD 17.49 Billion in 2034 from USD 9.49 Billion (2025) growing at a CAGR of 7.02% during 2026-2034.

The global somatostatin analogs market has shown steady growth due to increasing cases of hormone-related disorders and certain types of tumors. Somatostatin analogs are synthetic drugs used to regulate hormone secretion and are commonly prescribed for conditions such as acromegaly and neuroendocrine tumors. Growing awareness about endocrine disorders and improvements in diagnostic technologies have supported early detection and treatment. As healthcare systems expand access to specialized therapies, the use of somatostatin analog medications has increased in hospitals and specialty clinics.

Several key factors are driving the market's development. The rising prevalence of hormonal disorders and neuroendocrine tumors has increased the need for effective long-term treatment options. Pharmaceutical companies are investing in research and development to improve drug formulations and extend the duration of action of these medications. In addition, improved healthcare infrastructure and increasing healthcare spending in developing regions are contributing to wider patient access. Government support for rare disease treatment programs has also played a role in market expansion.

The future outlook for the somatostatin analogs market appears positive as medical research continues to explore new therapeutic applications. Advances in drug delivery systems, including long-acting injectable formulations, may enhance patient convenience and treatment outcomes. Increasing collaboration between biotechnology firms and pharmaceutical companies is expected to accelerate product development. As awareness of endocrine disorders grows and diagnostic capabilities improve, demand for effective hormone-regulating therapies is likely to rise in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Octreotide
  • Lanreotide
  • Pasireotide

By Application

  • Acromegaly
  • Neuroendocrine Tumors (NETs)
  • Others

COMPANIES PROFILED

  • Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma Inc, Peptron Inc, Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc, Pfizer Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SOMATOSTATIN ANALOGS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Octreotide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lanreotide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Pasireotide Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SOMATOSTATIN ANALOGS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Acromegaly Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Neuroendocrine Tumors (NETs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SOMATOSTATIN ANALOGS MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By Application
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By Application
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By Application
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By Application
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By Application
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL SOMATOSTATIN ANALOGS INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Novartis AG
    • 8.2.2 Sun Pharmaceutical Industries Ltd
    • 8.2.3 Midatech Pharma PLC
    • 8.2.4 Ipsen Pharma
    • 8.2.5 Chiasma Inc
    • 8.2.6 Peptron Inc
    • 8.2.7 Crinetics Pharmaceuticals
    • 8.2.8 Dauntless Pharmaceuticals
    • 8.2.9 Camurus AB
    • 8.2.10 Teva Pharmaceuticals Inc
    • 8.2.11 Pfizer Inc